Why Integra LifeSciences (IART) Stock Is Up Today

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

IART Cover Image

What Happened?

Shares of medical device company Integra LifeSciences (NASDAQ: IART) jumped 4.3% in the afternoon session after BMO Capital initiated coverage on the stock with a "Market Perform" rating and a $19 price target.

The firm noted that the return of Essig as chief executive officer provides operational continuity. The initiation followed other recent positive analyst actions, including an upgrade from Argus, which raised its rating from "Hold" to "Buy" with a $25.00 price target. BMO also pointed to early signs of recovery for the company, such as a first-quarter 2026 earnings beat and record production of its Integra Skin product.

The shares were trading at $18.09, up 4.5% from the previous close.

Is now the time to buy Integra LifeSciences? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Integra LifeSciences’s shares are extremely volatile and have had 32 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 8 months ago when the stock dropped 23% on the news that it reported third-quarter sales that missed expectations and provided a weak financial outlook. 

The company's revenue of $402.1 million fell short of Wall Street's projections. While its adjusted earnings per share of $0.54 surpassed estimates, this was overshadowed by disappointing forward-looking guidance. Integra's revenue forecast for the fourth quarter came in at $430 million, well below what analysts had anticipated. Adding to investor concerns, the company also lowered its adjusted earnings per share guidance for the full year.

Integra LifeSciences is up 50.6% since the beginning of the year, and at $18.09 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at only $264.25.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.04
+3.42 (1.40%)
AAPL  316.22
+2.83 (0.90%)
AMD  546.72
+29.31 (5.66%)
BAC  59.25
+0.95 (1.63%)
GOOG  356.24
-2.47 (-0.69%)
META  631.48
+28.36 (4.70%)
MSFT  384.36
+1.02 (0.27%)
NVDA  202.78
-1.34 (-0.66%)
ORCL  144.22
+3.73 (2.65%)
TSLA  406.55
+12.49 (3.17%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.